Emerging Cell Free DNA (cfDNA) Testing Market Trend 2025-2034: Labcorp Launches An Advanced Liquid Biopsy Test For Precision Oncology

How Is the Cell Free DNA (cfDNA) Testing Market Projected to Grow, and What Is Its Market Size?
Over the past few years, the market size for cell free dna (cfDNA) testing has seen a massive expansion. It's anticipated to surge from $8.74 billion in 2024 to $10.86 billion in 2025, which means a compound annual growth rate (CAGR) of 24.2%. The historic period's growth was primarily driven by factors including a surge in the usage of cfDNA testing in prenatal care, an increase in cfDNA analysis application, burgeoning interest in cfDNA research in diverse medical domains, and a rise in gaining approvals from regulatory authorities.

The market size for cell free dna (cfDNA) testing is projected to experience an enormous growth in the upcoming years, potentially expanding to a worth of $25.56 billion by 2029. This growth, accompanied by a compound annual growth rate (CAGR) of 23.9%, can be explained by the increasing shift towards individualized medicine, improvements in healthcare facilities, a larger aging population and mounting cancer incidences. Additional growth drivers include precision medicine growing in acceptance and awareness, accelerative adoption of liquid biopsy procedures, and massive investments along with funding into cfDNA research. The future landscape is also predicted to showcase certain trends such as utilization of liquid biopsy technologies, progress in Next-Generation Sequencing (NGS) technology, the drawing in of AI and machine learning into cfDNA testing, development of instant, on-site cfDNA tests and the adopting of cloud-based systems for storage and analysis of data.

What Are the Key Drivers Behind the Growth of the Cell Free DNA (cfDNA) Testing Market?
The cell-free DNA (cfDNA) testing market is expected to be propelled by the increasing cases of cancer. This complicated group of diseases is marked by the unruly growth and dissemination of abnormal cells throughout the body, leading to severe damage if left unchecked. Factors like aging populations, lifestyle changes, environmental effects, and improved detection and diagnostic methods contribute to cancer prevalence. With cfDNA testing, genetic mutations linked to cancer can be detected early on, often before any symptoms develop. Early detection enables immediate action, enhancing patient outcomes and survival rates by catching cancer in its earliest phases. As per the World Health Organization (WHO), a Switzerland-based intergovernmental entity, the number of new cancer instances is predicted to exceed 35 million in 2050, marking a 77% surge from the estimated 20 million cases in 2022. Hence, the increasing incidence of cancer is fuelling the expansion of the cfDNA testing market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15757&type=smp

Who Are the Major Industry Players Fueling Cell Free DNA (cfDNA) Testing Market Expansion?
Major companies operating in the cell free DNA (cfDNA) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC

Which Key Developments Are Influencing the Cell Free DNA (cfDNA) Testing Market?
Large corporations that are engaged in the cell-free DNA (cfDNA) testing market prioritize the advancement of groundbreaking technologies like liquid biopsy tests. These tests offer higher sensitivity, specificity, and functionality in identifying cancer-related mutations and genetic changes. Liquid biopsy testing provides diagnostic methods for oncologists to study the circulating cell-free DNA emitted by cancer cells, aiding the personalization of targeted therapy plans. For instance, in May 2023, U.S.-based Laboratory Corporation of America Holdings (Labcorp) introduced Labcorp Plasma Focus, designed specifically for patients with advanced or metastatic solid tumors. This revolutionary liquid biopsy test discerns circulating cell-free DNA (cfDNA) released by tumor cells obtained from a routine blood draw, ensuring minimal invasiveness, quick results, and enhanced access to precision oncology. It is capable of isolating clinically actionable biomarkers from various prevalent cancers including non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.

How Is the Segmentation of the Cell Free DNA (cfDNA) Testing Market Defined?
The cell free dna (cfDNA) testing market covered in this report is segmented -

1) By Product: Donor-Derived Cell-Free DNA, Circulating Cell-Free Tumor DNA, Cell-Free Fetal DNA
2) By Platforms: Next Generation Sequencing (NGS), rPCR And Multiplexed PCR, qPCR And dPCR, Other platforms
3) By Application: Oncology, Non-Invasive Prenatal Test (NIPT), Gynecology, Transplantation, Other Applications

Subsegments:
1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring, Graft Rejection Detection
2) By Circulating Cell-Free Tumor DNA: Cancer Detection, Minimal Residual Disease Monitoring, Liquid Biopsy
3) By Cell-Free Fetal DNA: Non-Invasive Prenatal Testing (NIPT), Fetal Genetic Disorder Screening

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/cell-free-dna-cfdna-testing-global-market-report

What Is the Leading Region in the Cell Free DNA (cfDNA) Testing Market?
North America was the largest region in the cell-free DNA (cfDNA) testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free DNA (cfDNA) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Cell Free DNA (cfDNA) Testing Global Market Report?

- Market Size Analysis: Analyze the Cell Free DNA (cfDNA) Testing Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Cell Free DNA (cfDNA) Testing Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Cell Free DNA (cfDNA) Testing Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Cell Free DNA (cfDNA) Testing Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15757

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.